YOLFTbeta
41

Vectorite Biomedical Inc.

4170 · TWO · Healthcare / Biotechnology

10.80TWD-0.05 (-0.46%)

Price History

Full chart

Market Stats

Previous Close10.85
Open10.55
Day Range10.55 – 10.80
52-Week Range11.50 – 18.15
Volume4.86K
Market Cap551.52M
P/E (TTM)4.68
Forward P/E0.00
EPS2.69
Dividend Yield0.00%
Beta0.39
50-Day Avg12.52
200-Day Avg13.23

About

Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. The company is involved in cell preparation product manufacturing; and collection and storage of immune cells. Its products are used in the field of infectious diseases and inflammation, cancer, and oncology. The company was incorporated in 2004 and is based in New Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOKechang Ou
  • HeadquartersNo. 97, Xintai 5th Road, New Taipei City, Taiwan, 22175, Taiwan
  • Websitehttps://www.vectorite.com.tw

Leadership

  • Kechang OuGeneral Manager
  • Hui Jing YouAccounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue26.54M24.54M28.77M42.91M55.85M57.77M61.41M
Growth (%)--7.52%+17.22%+49.16%+30.15%+3.43%+6.29%
Cost of Revenue23.72M22.63M31.24M42.21M39.43M40.80M39.72M
Gross Profit2.83M1.92M-2.47M707.00K16.42M16.97M21.68M
Gross Margin10.64%7.81%-8.60%1.65%29.40%29.37%35.31%
Operating Expense102.40M62.84M39.92M-29.83M32.55M42.94M43.59M
Operating Income-99.58M-60.93M-42.39M30.54M-16.13M-25.97M-21.91M
Operating Margin-375.19%-248.24%-147.34%71.16%-28.88%-44.96%-35.68%
EBITDA-79.97M-42.72M-25.94M-21.68M-6.97M-17.21M104.29M
EBITDA Margin-301.30%-174.06%-90.15%-50.51%-12.48%-29.79%169.84%
Net Income-90.27M-68.17M8.36M-26.41M-6.60M-40.05M96.17M
Net Income Margin-340.11%-277.75%29.05%-61.55%-11.82%-69.33%156.62%
R&D45.00M16.55M13.25M5.42M6.59M16.96M15.48M
R&D as % of Total Revenue169.53%67.43%46.04%12.64%11.81%29.35%25.21%
Interest Expense108.00K535.00K---011.00K
Interest Expense % of Total Revenue0.41%2.18%---0.00%0.02%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets389.00M369.09M492.64M465.82M452.10M412.78M509.56M
Total Liabilities48.87M24.00M25.71M24.49M21.25M23.20M24.48M
Total Equity285.75M344.61M466.51M440.90M430.44M389.16M484.71M
Cash115.32M28.76M39.20M27.87M25.32M30.60M25.71M
Total Debt20.27M------
Net Debt-95.05M-28.76M-39.20M-27.87M-25.32M-30.60M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-62.72M-36.90M-65.79M14.70M1.30M-11.51M-5.79M
Investing Cash Flow-18.88M-163.54M-41.67M-26.34M-3.82M16.36M-
Financing Cash Flow117.27M114.22M118.08M--200.00K-
Capital Expenditure4.31M771.00K1.79M888.00K4.75M2.84M4.00M
Free Cash Flow-67.03M-37.67M-67.59M13.81M-3.46M-14.35M-9.78M
FCF to OCF106.87%102.09%102.73%93.96%-266.33%124.68%169.09%

Key Statistics & Ratios

Market Cap551.52M
Enterprise Value398.63M
Trailing P/E4.68
Forward P/E0.00
Price / Sales10.06
Price / Book1.11
EPS2.69
Book Value11.67
Revenue (TTM)54.81M
Gross Profit (TTM)17.04M
EBITDA-16.17M
Profit Margin215.70%
Operating Margin-31.82%
Return on Equity26.13%
Return on Assets-3.03%
Shares Outstanding43.77M
Shares Float25.40M
Beta0.39
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 27, 20151100.566:1000